lumigan cost is used to treat certain types of glaucoma and other causes of high pressure inside the eyes.While Latisse and Lumigan are the same thing, there are important difference in how they are used. Latisse users are directed to carefully apply the liquid to the eyelash. Lumigan users put drops of the drug right into the eye.
But the FDA is less than pleased with how Allergan presents the safety information associated with the product. In a September 10 letter to Allergan, the FDA lists a number of safety and marketing claims on the Latisse site that it calls “misleading because they omit and minimize risks associated with Latisse treatment”.
One piece of information that the FDA sites Latisse for omitting is that those who fail to use the Latisse applicators properly are at risk for developing bacterial keratitis, a fast-developing eye infection that can cause blindness. Also highlighted in the letter is that Latisse notes that “increased brown iris pigmentation has occurred when similar medications were instilled directly into the eye to treat elevated intraocular pressure/glaucoma.” This statement is incorrect, explains the FDA, because these “similar” medications that Latisse refers to here is actually Lumigan, which has shown to permanently change iris pigmentation in patients who take that drug.